Johnson & Johnson

Company facts

Industry

Pharmaceutical Preparations

Headquarters

New Brunswick, New Jersey

Most recent report

8-K, filed Aug 4, 2026

Incorporated

New Jersey

Filings on record

1,001+ filings

On EDGAR

CIK 200406

Fiscal year ends

January

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 2 of 10 sections worth reading, with 2 positive, 8 notable, and 6 negative flags.

• Financial Statements (Item 1)

  Core financial data: revenue up, net earnings flat, talc reserve up, litigation updates.
  Notable

  • Supplier finance obligations stable at $0.7B as of June 28, 2026; payment terms unchanged at 90 days.
  • Effective tax rate 15.5% for H1 2026 vs 17.8% prior year; benefited from share-based comp deductions (2.9% rate reduction).
  • Agreed to acquire Firefly Bio for $1B in cash, expected to close in Q3 2026; adds degrader antibody conjugate platform.
  • CARVYKTI patent suit in EU by 2seventy bio; U.S. government intervened in May 2026; oral hearing March 2027.
  • Fortis Advisors judgment of $0.8B paid in January 2026; booked in prior period, now cash outflow reflected.
  • New Innovative Medicine supply chain restructuring initiated; estimated $650M-$750M cost, $200M recorded in Q2 2026.
  Negative

  • Commercial paper balance reduced to $9.9B from $15.7B at end of Q1 2026, but still high at 3.68% rate.
  • Talc reserve now $3.7B present value; ~76,000 plaintiffs pending; securities class action certiorari denied.

• Management's Discussion (Item 2)

  Detailed sales drivers, STELARA decline, new competition, restructuring, and Orthopaedics separation plan.
  Positive

  • DARZALEX sales $8.2B in H1 2026, up 20.6% total, driven by share gains and market growth.
  • TREMFYA sales $3.7B in H1 2026, up 70.6% total, with strong IBD launch momentum.
  Notable

  • Orthopaedics separation plan; $0.4B separation costs in H1 2026.
  • Net debt improved to $28.2B from $31.9B a year ago; cash from operations $11.1B in H1.
  Negative

  • SIMPONI biosimilars entered Europe in Q2 2026; U.S. entrant later in 2026 will cut future sales.
  • OPSUMIT generic entered U.S. late Q2 2026, likely reducing future sales.
  • Talc litigation charges of $0.8B in H1 2026, versus a $7.0B reversal in H1 2025.
  • MedTech segment margin fell to 13.8% in H1 2026 from 15.9%, hit by separation costs, tariffs, and R&D.

What changed: Jun 2026 vs. Mar 2026

About 19% of JNJ's Jun 2026 10-Q is new information. 81 paragraphs were added, 161 changed, and 33 removed. Below are the most important lines SECSift identified.

• Item 2 99
• Item 1 91
• Item 5 1